Rani Therapeutics Announces Partnership with ProGen on Development of Oral Obesity Treatment

~ New RT-114 obesity program combines ProGen's FC Fusion protein conjugated GLP-1/GLP-2 dual agonist, PG-102, with the RaniPill® capsule designed to provide a differentiated oral delivery mechanism with bioavailability comparable to subcutaneous injection ~ ~ Rani to host conference call today at 8:00 a.m. ET/5:00 a.m. PT ~ "This partnership brings together Rani's oral biologics delivery expertise with ProGen's two decades of experience in Fc-fusion proteins to enable development of a potentially unique ora ...